Madrigal Pharmaceuticals Inc recorded a cumulative net loss of $-309 million during 12 month ending in the first quarter 2026.
The Healthcare sector has seen employees of 122 other companies achieving higher income per employee. While Madrigal Pharmaceuticals Inc 's total ranking has deteriorated compared to the previous quarter from 2974 to 3304.

What is Income per Employee Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Net Income per Employee▼

None ▼

Net Income per Employee▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

MDGL Net Income per Employee	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter
Y / Y Net Income Change	-	-	-	-	-
Net Income per Employee (TTM) $	-338,183	-315,064	-315,984	-308,086	-427,966
MDGL's Total Ranking	# 3304	# 2974	# 2538	# 3476	# 1020
Seq. Net Income Change	-	-	-	-	-

MDGL Company Profile >> Back to MDGL Efficiency Comparisons >> Compare MDGL Net Income per Employee to its Competitors

MDGL Net Income per Employee Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 123
Healthcare Sector	# 404
Overall Market	# 3304

Net Income per Employee Statistics
High	Average	Low
$ -27,481	$ -192,076	$ -566,852
(Sep 30 2017)		(Sep 30 2024)

News about Madrigal Pharmaceuticals Inc Income per employee

Madrigal Pharmaceuticals Leaps Forward with Upsized $600 Million Public Offering and Aims to Transform NASH Treatment Landscape

Madrigal Pharmaceuticals Announces Upsized $600 Million Public Offering and Record Net Loss
CONSHOHOCKEN, Pa., March 18, 2024 - Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a leading biopharmaceutical company specializing in novel therapeutics for nonalcoholic steatohepatitis (NASH), recently disclosed the pricing of its underwritten public offering. The company plans to offer 750,000 shares of its common stock at a public offering price of $260.0000 per share. Additionally, Madrigal will offer pre-funded warrants to certain investors, exercisable for 1,557,692 shares of common stock at $259.9999 per pre-funded warrant. The offering generated substantial interest, leading to a $100 million increase in size subsequent to the initial announcement.
The gross proceeds from the offering are projected to be approximately $600 million, before deducting the underwriting discounts, commissions, and other expenses. Madrigal has also granted the underwriters a 30-day option to purchase an additional 346,153 shares of common stock at the public offering price, subject to underwriting discounts and commissions.

Madrigal Pharmaceuticals Announces Proposed Public Offering to Accelerate Innovation in NASH Therapeutics

Madrigal Pharmaceuticals Embarks on $500 Million Public Offering to Fuel Innovation in NASH Therapeutics
CONSHOHOCKEN, Pa., March 18, 2024 - Madrigal Pharmaceuticals, a leading biopharmaceutical company focused on groundbreaking treatments for nonalcoholic steatohepatitis (NASH), has recently unveiled its plans to undertake a substantial public offering of $500 million in shares of common stock and pre-funded warrants. With the company s unwavering dedication to addressing the urgent need for effective NASH therapies, this public offering marks a significant milestone in Madrigal s pursuit of innovation and growth.
This exciting development comes on the heels of Madrigal Pharmaceuticals cumulative net loss of $-374 million during the 12-month period ending in the fourth quarter of 2023, as revealed in recent financial reports. Despite this, Madrigal remains resolute in its commitment to making substantial strides in the challenging landscape of NASH treatment.

Companies with similar Income per Employee for 12 month ending Mar 31 2026, within Healthcare Sector

Income per Employee

Income 12 month ending Mar 31 2026

Number of Employees Mar 31 2026

Date modified: 2026-08-30T14:48:47+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.